Voluntis adds Toujeo to basal insulin management app, with eyes on more

At its U.S. launch, Voluntis' Insulia diabetes management companion worked for two types of basal insulin. Now the French company is adding a third, with plans to integrate all types of basal insulin into the app. (Voluntis)

When Voluntis launched its diabetes management app, it worked with two types of basal insulin. Now, the company has scored FDA clearance and a CE mark to add Sanofi’s higher-concentration Toujeo to the mix.

The Insulia app earned twin U.S. and EU OKs in December 2016 to be used with Sanofi’s Lantus and Novo Nordisk’s Levemir. Designed for Type 2 diabetes patients who are treated with basal, or background, insulin, the Insulia app aims to help these patients meet their recommended blood glucose targets.

The Insulia diabetes management companion comprises a mobile app for the patient and a web portal for his or her physician. The doctor prescribes insulin and creates an individualized treatment plan using the portal. The patient then receives insulin dose recommendations and coaching messages based on real-time blood glucose data.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The new regulatory nods come just after Insulia’s U.S. launch and just ahead of its European debut. Voluntis is working to integrate all basal insulins and all GLP-1/basal insulin combos into Insulia.

In March, Paris-based Voluntis expanded its partnership with Sanofi to run pilot programs based on the Insulia platform in North America and Europe. The duo originally teamed up in 2011 to develop software that helps diabetes patients manage their basal and bolus insulin.

"Despite the availability of new medicines for the treatment of diabetes, we see that outcomes are not sufficiently improving and that more than half of patients are not well controlled," Peter Guenter, executive vice president of Sanofi’s diabetes and cardiovascular unit, said at the time. "With this in mind, Sanofi is focusing on a beyond-the-pill approach. We know that diabetes management is a 24/7 job, and we recognize that the right tools need to be developed to realize better outcomes. The long-term alliance we have with Voluntis will help us to reach that goal."

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.